10-K
Annual Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
42 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 473,966,000 | 344,067,000 |
Marketable securities | 49,443,000 | 49,335,000 |
Accounts receivable, net | 47,013,000 | 87,862,000 |
Inventory | 56,341,000 | 83,107,000 |
Other receivables | 35,480,000 | 606,000 |
Prepaid expenses and other current assets | 22,208,000 | 19,410,000 |
Total current assets | 684,451,000 | 584,387,000 |
Property and equipment, net | 226,711,000 | 252,648,000 |
Operating lease right-of-use assets | 60,450,000 | 57,290,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 62,329,000 | 15,671,000 |
Other noncurrent assets | 2,913,000 | 4,129,000 |
Total assets | 1,041,365,000 | 918,636,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 12,733,000 | 12,909,000 |
Accrued compensation and related benefits | 42,500,000 | 33,615,000 |
Accrued expenses and other current liabilities | 39,971,000 | 41,165,000 |
Deferred revenue | 23,902,000 | 20,658,000 |
Products And Services, Excluding Grant Revenue | 23,900,000 | — |
Operating lease liabilities | 10,985,000 | 9,286,000 |
Contingent consideration, current | 23,363,000 | 0 |
Total current liabilities | 153,454,000 | 117,633,000 |
Contingent consideration, noncurrent | 1,237,000 | 0 |
Operating lease liabilities, noncurrent | 73,376,000 | 73,327,000 |
Deferred revenue, noncurrent | 10,501,000 | 12,513,000 |
Other noncurrent liabilities | 6,471,000 | 5,029,000 |
Total liabilities | 245,039,000 | 208,502,000 |
Stockholders' equity: | ||
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 and 2024 | 0 | 0 |
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 127,691,329 (Class A 117,612,457, Class B 10,078,872) and 122,291,837 (Class A 108,235,004, Class B 14,056,833) shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 2,000 |
Additional paid-in capital | 2,306,690,000 | 2,177,672,000 |
Accumulated deficit | (1,510,591,000) | (1,467,047,000) |
Accumulated other comprehensive income (loss) | 225,000 | (493,000) |
Total stockholders’ equity | 796,326,000 | 710,134,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,306,690,000 | 2,177,672,000 |
Accumulated Deficit | (1,510,591,000) | (1,467,047,000) |
Accumulated Other Comprehensive Income (Loss) | 225,000 | (493,000) |
Total liabilities and stockholders’ equity | 1,041,365,000 | 918,636,000 |